Key result
Self-monitoring of coagulation status significantly reduced the risk of thromboembolic events (RR 0.58) compared to standard clinic monitoring in patients on long-term vitamin K antagonist therapy.
Why the study?
Does self-monitoring of coagulation status using point-of-care coagulometers reduce thromboembolic events and prove cost-effective in patients receiving long-term vitamin K antagonist therapy?
Systematic Review (n=8,763)
Does self-monitoring of coagulation status using point-of-care coagulometers reduce thromboembolic events and prove cost-effective in patients receiving long-term vitamin K antagonist therapy?
Relative Risk: 0.58 (95% CI 0.4–0.84)
p-value: p=0.004
Self-monitoring of oral anticoagulation with point-of-care coagulometers significantly reduces thromboembolic events and is likely cost-effective, particularly for patients with artificial heart valves.
No takes yet. Share an insight, caveat, or question.
Self-monitoring may prove cost-effective for long-term VKA patients; leaves open need for updated RCTs on implementation and outcomes.
Sharma et al. (2015) conducted a systematic review in Atrial fibrillation or heart valve disease requiring long-term anticoagulation (n=8,763). Point-of-care coagulometers for self-monitoring vs. Standard clinic monitoring was evaluated on Thromboembolic events (RR 0.58, 95% CI 0.40 to 0.84, p=0.004). Self-monitoring of coagulation status significantly reduced the risk of thromboembolic events (RR 0.58) compared to standard clinic monitoring in patients on long-term vitamin K antagonist therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: